Breast Cancer Clinical Trial
Official title:
The Role of Serotonin in Hot Flashes After Breast Cancer
The purpose of this proposal is to improve our understanding of the role of tryptophan and serotonin in hot flashes. The main hypothesis is that alterations in tryptophan and serotonin levels are involved in the induction of hot flashes in women with breast cancer and genetic variations in the serotonin receptors and transporters also play a role.
Among women with breast cancer, hot flashes are a frequent, severe and bothersome symptom.
For this group, hot flashes are negatively related to mood, affect, and daily activities and
can compromise compliance with life-saving medications (e.g., tamoxifen). Over 60% of breast
cancer survivors report hot flashes, with 59% stating they are extremely severe and 44%
reporting them to be extremely bothersome. Unfortunately, limitations in our understanding
of hot flash physiology limit clinicians' abilities to fully treat this symptom. Although
the current non-hormonal treatment of choice for hot flashes after breast cancer targets the
central serotonin system (e.g., paroxetine, venlafaxine), the role of serotonin in hot
flashes has not been directly tested. Because the effectiveness of these agents has been
based largely on improvement in subjective reporting of hot flashes, it is not clear whether
benefits are due to physiological effects on hot flashes or due to improvements in mood or
other related symptoms. In addition, these and other currently available treatments are not
acceptable, appropriate, or effective for all women with breast cancer. Understanding the
physiological mechanisms involved in hot flashes after breast cancer will enable us to
develop more targeted behavioral and/or pharmacological therapies to be used in lieu of, or
in addition to, currently available therapies so that we can eradicate hot flashes and
improve the quality of life for women with breast cancer.
Results implicating direct effects of tryptophan and serotonin on objective hot flashes will
help guide the development of improved interventions for alleviating hot flashes in women
with breast cancer. These interventions may target the central serotonin system either
behaviorally (e.g., diet) or pharmacologically (e.g., alternative drug therapeutics). If
direct manipulation of tryptophan and serotonin does not affect hot flashes, these findings
will be equally as useful in guiding future research on non-serotonin related etiologies and
interventions. Findings from this study will ultimately be used to eradicate hot flashes as
a frequent, severe and bothersome breast cancer treatment related condition, thereby,
improving quality of life for all women with breast cancer.
;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |